NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cirrus Therapeutics

Cirrus Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://cirrustx.com/

Last Round

Seed

Oct 2, 2025

Total Funding Raised

$11M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Cirrus Therapeutics is a biotechnology company developing gene and cell therapies for ocular immunology to treat conditions like age-related macular degeneration (AMD).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

ocular immunologyAAV gene therapydry age-related macular degenerationAMDgene therapygeographic atrophyGAIRAK-Mcell therapyRPE cell therapyadeno-associated virusophthalmologypreclinical biotechblinding diseases

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cirrus Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Cirrus Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cirrus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 2, 2025

Key People

Founding team and executive leadership

Ying Kai Chan

Co-Founder And CEO

Founding Team

Edward F. Finn

Consulting CFO

Executive Team

Cirrus Therapeutics Investors

Notable investors and investment history

Cirrus Therapeutics investors
InvestorRounds
SEEDS CapitalSeed
ClavystBioSeed
Polaris PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Grew 120% QoQ from 5 to 11 employees.

  • Oct 2, 2025

    $11M round led by ClavystBio.

Cirrus Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cirrus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cirrus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range12
Year Founded2022
Last FundingOct 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.